Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...

Meanwhile, Novo had agreed supply deals with Hims and several of its larger rivals. The idea was to give their existing semaglutide patients an easy on-ramp to branded Wegovy.

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Last month, the two announced a partnership that would enable Wegovy to be directly purchased by patients via Hims’ ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth ...

Novo Nordisk drops Hims & Hers because it was selling and promoting a cheaper copycat of Wegovy, its weight loss drug.

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Dive Brief: Novo Nordisk is terminating a marketing deal for its obesity drug Wegovy with Hims & Hers Health just eight weeks after it began, claiming the telehealth company “has failed to adhere to ...